The Drug Regulatory Authority of Pakistan (DRAP) has issued a public warning regarding the usage of batch L-083 of Weena Syrup, a widely consumed product produced by Ms Swat Pharmaceuticals in Saidu Sharif Swat, ARY News reported.
The alert comes as a result of potential health risks associated with the incorrect usage of the syrup, commonly employed in the treatment and prevention of iron deficiency anemia.
According to the DRAP recall notice, the defective batch can lead to common side effects, including various gastrointestinal distress symptoms such as nausea, diarrhoea, vomiting, abdominal pain, constipation, and dark or discoloured stool. Citizens are strongly advised against using this specific batch of Weena Syrup, and the manufacturer has been directed to immediately recall the identified batch from the market, according to ARY News.
Pharmacies have been instructed to halt the supply of batch L-083, and any remaining stock is to be quarantined and returned to the supplier or the manufacturing company. To ensure the effective recall of the defective products, DRAP's regulatory field force and provincial health departments will increase surveillance in the market.
This announcement follows a recent ban imposed by the Punjab government on five cough syrups, prompted by a World Health Organisation (WHO) alert. The WHO investigation, initiated after a complaint from the Maldives, confirmed the presence of "excessive amounts of alcohol" in the cough syrups. Punjab's Caretaker Health Minister, Jamal Nasir, has vowed to extend the crackdown to all medical stores in the province to ensure the removal of the identified cough syrups from circulation.
Caretaker Minister Nasir emphasised that these companies were not only distributing their products within the country but also exporting them abroad. Strict actions are promised against those responsible for potentially tarnishing the country's reputation. The health ministry remains vigilant in safeguarding public health and maintaining the quality and safety standards of pharmaceutical products in the market, ARY News reported.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)